View:

Download DOC

Download PDF

Download XLS

Table of Contents

Table of Contents

                                                                    Exhibit 99.1

Contact:
Marc S. Hanover
GTx, Inc.
President and Chief Operating Officer
901-523-9700

GTX, INC. ANNOUNCES POSITIVE CLINICAL RESULTS AND DEVELOPMENT PLANS FOR OSTARINE

MEMPHIS, TENN. - September 7, 2005 - GTx, Inc. (Nasdaq: GTXI), The Men's Health
Biotech Company, announced today that results from its Phase I clinical trials
for ostarine, its second selective androgen receptor modulator (SARM), were
consistent with anabolic activity without evidence of unwanted androgenic side
effects on prostate and skin sebaceous glands. GTx intends to begin a Phase II
clinical trial of ostarine for the treatment of muscle wasting associated with
burns during the fourth quarter of 2005.

"We are excited with the outcome of our Phase I clinical trials of ostarine. Now
that ostarine is poised to enter Phase II clinical trials, it becomes our lead
SARM compound," said Mitchell Steiner, MD, chief executive officer of GTx.
"Results from our recently completed multiple-ascending dose clinical trial have
allowed us to pick doses of ostarine to advance into Phase II clinical trials.
We have also zeroed in on developing ostarine for muscle wasting associated with
an acute condition, burns, for which we believe ostarine fills an unmet medical
need and which may provide us with an efficient path to market. We remain
excited by other, broader market possibilities for ostarine, such as muscle
wasting associated with andropause, and we intend to initiate a second Phase II
clinical trial of ostarine for this indication in the first half of 2006."

About Ostarine

Ostarine is a non-steroidal, oral SARM, all rights to which are held by GTx. GTx
believes that ostarine has the potential to treat muscle wasting associated with
chronic conditions, such as end-stage renal disease, frailty and andropause, as
well as muscle wasting associated with acute conditions, such as burns.

Ostarine is the second SARM that GTx has brought from discovery into clinical
trials. GTx also discovered andarine, a SARM that GTx and its collaborator,
Johnson & Johnson's subsidiary, Ortho Biotech Products L.P., are developing to
treat cancer cachexia.


Planned Phase II Clinical Trials for Ostarine

GTx plans to initiate Phase II clinical trials of ostarine first for muscle
wasting associated with burns because acute indications have a relatively
expeditious and defined clinical development and regulatory pathway. Burn
patients are hypermetabolic and lose significant lean body weight, which
adversely affects their healing and recovery. GTx expects to begin its Phase II
clinical trial of ostarine for muscle wasting associated with burns in the
fourth quarter of 2005. Studies have already established proof-of-concept for
the use of anabolic agents in the treatment of burns. Because ostarine has a
long half life (24 hours) and provides levels of circulating androgens
unattainable with anabolic steroidal agents, GTx believes that this selective,
potent, non-steroidal anabolic agent would be an important step forward in the
treatment of burn patients.





"We believe that the treatment of burn patients represents an excellent first
path for GTx to pursue for ostarine," said Dr. Steiner. "A powerful anabolic
agent without unwanted steroidal side effects could help speed the recovery of
burn victims. For GTx, the treatment of burn patients offers a relatively
expeditious route to market for its lead SARM."

GTx plans to continue clinical development of ostarine for chronic muscle
wasting due to low testosterone in aging men (a condition also known as
andropause). Between 30 and 60 years of age, men on average gain a pound of fat
and lose a half pound of muscle, and muscle loss accelerates after age 60. This
loss of muscle mass can lead to frailty and loss of independence. GTx plans to
initiate Phase II clinical testing for the treatment of andropause during the
first half of 2006.


About Ostarine's Phase I Multiple Ascending Dose Clinical Trial Results

The Phase I multiple-ascending dose clinical trial evaluated the safety,
tolerability and specific pharmacodynamic characteristics of ostarine in a
double-blind, placebo-controlled study in 48 healthy male volunteers, 18-45
years of age, and 12 elderly males with truncal obesity, who averaged 68 years
of age. Safety and pharmacodynamic measurements were taken at the beginning of
the study and after 14 days of daily oral dosing. These measurements included
routine blood chemistry and hematology, sex hormones and gonadotropins, serum
prostate specific antigen, metabolic markers of bone and muscle, cutaneous sebum
analysis and DEXA scanning for body composition.

Ostarine is designed to have anabolic building activity without unwanted
androgenic side effects on prostate and skin sebaceous glands. Overall, clinical
laboratory values and hormonal effects determined from the study were consistent
with anabolic activity. Comparisons of DEXA assessments from the beginning of
the study to DEXA assessments after 14 days showed positive changes in body
composition, with lean body mass and fat mass in study patients moving in a
direction consistent with anabolic activity. Based on other tests, ostarine did
not appear to have unwanted side effects on the prostate or the skin. GTx
believes that these observations support the potential ability of ostarine to
selectively modulate androgen receptors in a tissue-specific manner.

There were no drug-related serious adverse events related to ostarine in the
clinical trial. Doses that were found to be safe in this study were selected to
enter Phase II testing later this year.

About GTx

GTx is a biopharmaceutical company dedicated to the discovery, development and
commercialization of therapeutics for cancer and serious conditions related to
men's health. GTx's lead drug discovery and development programs are focused on
small molecules that selectively modulate the effects of estrogens and
androgens, two essential classes of hormones. GTx, headquartered in Memphis,
Tenn., currently has four clinical programs. GTx is developing ACAPODENE(R)
(toremifene citrate), a selective estrogen receptor modulator, or SERM, in two
separate clinical programs in men: (1) a pivotal Phase III clinical trial for
the treatment of serious side effects of androgen deprivation therapy for
advanced prostate cancer and (2) a pivotal Phase III clinical trial for the
prevention of prostate cancer in high risk men with precancerous prostate
lesions. In its third clinical program, GTx is developing ostarine for the
treatment of muscle wasting associated with acute conditions such as burns and
chronic conditions such as andropause. GTx expects to begin Phase II clinical
trials of ostarine for muscle wasting associated with burns in the fourth
quarter of 2005 and for andropause during





the first half of 2006. In its fourth clinical program, GTx and its
collaborator, Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson,
are developing andarine, another one of GTx's SARMs, for the treatment of cancer
cachexia. GTx is working with Ortho Biotech to plan a Phase II clinical trial of
andarine.

Forward-Looking Information is Subject to Risk and Uncertainty

This press release contains forward-looking statements, including, without
limitation, statements related to GTx's planned clinical trials of ostarine and
its other research and development programs. These forward-looking statements
are based upon GTx's current expectations. Forward-looking statements involve
risks and uncertainties. GTx's actual results and the timing of events could
differ materially from those anticipated in such forward-looking statements as a
result of these risks and uncertainties and other important factors, which
include, without limitation, risks that GTx will not be able to commercialize
its product candidates if clinical trials do not demonstrate safety and efficacy
in humans; risks related to GTx's dependence on third parties; and if the
Company is not able to obtain required regulatory approvals, the Company will
not be able to commercialize its product candidates. You should not place undue
reliance on these forward-looking statements, which apply only as of the date of
this press release. The annual report filed on Form 10-K-A with the U.S.
Securities and Exchange Commission (the "SEC") on August 3, 2005 contains under
the heading "Additional Factors That Might Affect Future Results," a more
comprehensive description of these and other important factors and risks to
which GTx is subject. GTx expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any such
statements are based.